@article{dfa8f6390a2348b3a09695bdf96a4bd8,
title = "Tetrahydrocannabinol Has Potential for Treating Agitation in Alzheimer's Disease",
author = "Rosenberg, {P. B.} and Outen, {J. D.} and H. Amjad and Burhanullah, {M. H.} and R. Vandrey and Monette, {P. J.} and Forester, {B. P.}",
note = "Funding Information: Paul Rosenberg has received research support from the National Institute on Aging, the Alzheimer's Association, Lilly, Functional Neuromodulation (FNMI), Abbvie, Alzheimer's Disease Cooperative Study (ADCS), Alzheimer's Disease Trials Research Institute (ATRI), and the Alzheimer's Clinical Trials Consortium (ACTC). He also performs consulting and advising for GLG, Leerink, Otsuka, Avanir, Bionomics, ITI, IQVIA, and the Food and Drug Administration. He has no stocks, royalties, or patents to disclose. Funding Information: Brent Forester receives grant support from Biogen, Eli Lilly, the Rogers Family Foundation, the Spier Family Foundation, and the National Institute on Aging. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
month = nov,
doi = "10.1016/j.jagp.2019.05.014",
language = "English (US)",
volume = "27",
pages = "1174--1176",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "11",
}